



Patient ID SA00048117	Patient Name SAMPLEREPORT, SLC1B	Birth Date 1966-06-10	Gender F	Age 46
Order Number SA00048117	Client Order Number SA00048117	Ordering Physician Client, Client	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 30 Jul 2012 13:00		

Rapid DNA Extraction

Comment

MCR

Genomic DNA was extracted.

Received: 31 Jul 2012 10:25

Reported: 31 Jul 2012 10:50

QA Environment

Performing Site Legend

Code	Laboratory	Address
MCR	Mayo Clinic Dept. of Lab Med and Pathology	200 First Street SW, Rochester, MN 55905

Patient ID SA00048117	Patient Name SAMPLEREPOR, SLC1B	Birth Date 1966-06-10	Gender F	Age 46
Order Number SA00048117	Client Order Number SA00048117	Ordering Physician Client, Client	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 30 Jul 2012 13:00		

SLCO1B1 Genotype, Statin, B

SLCO1B1 Genotype Result

MCR

TC detected

clinical monitoring. Please contact the laboratory at 1-800-533-1710 for further information about pharmacogenomic testing.

SLCO1B1 Interpretation

MCR

This individual is heterozygous (TC) for the SLCO1B1 *5 (c.521T>C, p.V174A) allele. This genotype is associated with decreased transporter activity and an increased risk for simvastatin-associated myopathy. A decrease in simvastatin dose or administration of an alternative statin therapy may be considered.

Targeted analysis of the SLCO1B1 *5 (c.521T>C, p.V174A, transcript NM_006446.4) allele is performed by a polymerase chain reaction (PCR)-based 5'-nuclease assay using fluorescently labeled detection probes. This DNA test will not detect all SLCO1B1 genetic variants.

CAUTIONS:

Rare variants may be present that could lead to false negative or positive results. If results obtained do not match the clinical findings (phenotype), additional testing should be considered.

ADDITIONAL INFORMATION

Absence of the *5 allele does not rule out the possibility that a patient harbors another variant that can impact drug side effects. While SLCO1B1 genotype has been shown to affect systemic exposure of other statins, there is less evidence demonstrating a clinical association between SLCO1B1 genotype and myopathy with statins other than simvastatin.

Samples may contain donor DNA if obtained from patients who received heterologous blood transfusions or allogeneic blood or marrow transplantation. Results from samples obtained under these circumstances may not accurately reflect the recipient's genotype. For individuals who have received blood transfusions, the genotype usually reverts to that of the recipient within 6 weeks. For individuals who have received allogeneic blood or marrow transplantation, a pre-transplant DNA specimen is recommended for testing. SLCO1B1 genetic test results in patients who have undergone liver transplantation may not accurately reflect the patient's SLCO1B1 status. Laboratory developed test.

For additional information regarding pharmacogenomic genes and their associated drugs, please see the Pharmacogenomic Associations Tables on the Mayo Medical Laboratories webpage, www.mayomedicallaboratories.com. This resource also includes information regarding enzyme inhibitors and inducers, as well as potential alternate drug choices. Please note that the information at this link is educational material intended for health care professionals and may not be comprehensive. This educational material is not intended to supersede the care provider's experience and knowledge of her/his patient to establish a diagnosis or a treatment plan. All medications require careful

Reviewed by

MCR

Jamie Bruffat

Received: 31 Jul 2012 10:25

Reported: 31 Jul 2012 10:46

Performing Site Legend

Code	Laboratory	Address
MCR	Mayo Clinic Dept. of Lab Med and Pathology	200 First Street SW, Rochester, MN 55905